Abemaciclib in Newly Diagnosed Meningioma Patients

Status Not yet recruiting

Clinical Trial Summary

This study is being done to learn about how an investigational drug called abemaciclib works in treating patients with a newly-diagnosed grade 3 meningioma. Abemaciclib is a drug that is approved by the FDA, but not for brain tumors. Participants who consent to the trial will have surgical tissue collected from the planned surgical resection and tested. If the tissue shows positive results for RB cells and participants are qualified, they will be enrolled and receive study treatment two to five weeks after completing standard-of-care radiation therapy. This is a randomized clinical trial which means that participants will be randomly assigned to a treatment based on chance, like a flip of a coin. Neither the participant nor the researcher chooses the assigned group. Randomization will help the researchers study how the drug works by comparing the difference between the study drug and the placebo and how they work in treating brain tumors. This is a double-blinded study, which means that neither the participant nor the study team will know which treatment the participant is receiving.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Meningioma

Clinical Trial Details

NCT number	NCT05940493
Study type	Interventional
Source	St. Joseph's Hospital and Medical Center, Phoenix
Contact	Ivy Research Navigator
Phone	602-406-8605
Email	research@ivybraintumorcenter.org
Status	Not yet recruiting
Phase	Phase 2
Start date	June 15, 2024
Completion date	December 2031

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04081701` - 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.	Phase 4
Recruiting	`NCT03631953` - Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas	Phase 1
Completed	`NCT03273712` - Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)	Phase 2
Recruiting	`NCT04367779` - Research of Biomarkers of Response to Proton Beam Therapy in Pediatric and Adult Patients.
Withdrawn	`NCT00985036` - Vascular Endothelial Growth Factor (VEGF) Levels in Brain Tumor Patients	N/A
Completed	`NCT01347307` - Stereotactic Body Radiotherapy for Spine Tumors	N/A
Completed	`NCT01811524` - The Etiology and Progression of Brain Tumors	N/A
Completed	`NCT03648034` - Effects of Scalp Nerve Block With Ropivacaine on Postoperative Recovery Quality	N/A
Recruiting	`NCT06036706` - Neurocognitive Impact of Different Irradiation Modalities for Patients With Grade I-II Skull Base Meningioma:	N/A
Recruiting	`NCT06014905` - Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma	Phase 1
Not yet recruiting	`NCT04386642` - Tranexamic Acid Reduce Blood Loss in Meningioma Resection	Phase 4
Active, not recruiting	`NCT04595786` - The Safety of Intravenous Tranexamic Acid in Patients Undergoing Supratentorial Meningiomas Resection	N/A
Active, not recruiting	`NCT04305470` - Gleolan for Visualization of Newly Diagnosed or Recurrent Meningioma	Phase 3
Completed	`NCT01967823` - T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer	Phase 2
Not yet recruiting	`NCT02978677` - Proton Dose Escalation for Patients With Atypical or Anaplastic Meningiomas	N/A
Active, not recruiting	`NCT02933736` - Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients	Early Phase 1
Completed	`NCT02267928` - Information Presentation Formats	N/A
Completed	`NCT00589784` - Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma	Phase 2
Active, not recruiting	`NCT03071874` - Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas	Phase 2
Recruiting	`NCT05416567` - Embolization for Meningioma	N/A